- Home
- SCD vs ACIU Comparison
SCD vs ACIU Comparison
Compare SCD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- ACIU
- Stock Information
- Founded
- SCD 2003
- ACIU 2003
- Country
- SCD United States
- ACIU Switzerland
- Employees
- SCD N/A
- ACIU N/A
- Industry
- SCD Trusts Except Educational Religious and Charitable
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SCD Finance
- ACIU Health Care
- Exchange
- SCD Nasdaq
- ACIU Nasdaq
- Market Cap
- SCD 265.9M
- ACIU 213.3M
- IPO Year
- SCD N/A
- ACIU 2016
- Fundamental
- Price
- SCD $15.20
- ACIU $2.14
- Analyst Decision
- SCD
- ACIU Strong Buy
- Analyst Count
- SCD 0
- ACIU 1
- Target Price
- SCD N/A
- ACIU $12.00
- AVG Volume (30 Days)
- SCD 62.6K
- ACIU 162.6K
- Earning Date
- SCD 01-01-0001
- ACIU 08-05-2025
- Dividend Yield
- SCD 9.63%
- ACIU N/A
- EPS Growth
- SCD N/A
- ACIU N/A
- EPS
- SCD N/A
- ACIU N/A
- Revenue
- SCD N/A
- ACIU $36,362,036.00
- Revenue This Year
- SCD N/A
- ACIU N/A
- Revenue Next Year
- SCD N/A
- ACIU $533.21
- P/E Ratio
- SCD N/A
- ACIU N/A
- Revenue Growth
- SCD N/A
- ACIU 86.71
- 52 Week Low
- SCD $11.33
- ACIU $1.43
- 52 Week High
- SCD $15.87
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- SCD 44.04
- ACIU 49.10
- Support Level
- SCD $14.79
- ACIU $2.05
- Resistance Level
- SCD $15.25
- ACIU $2.50
- Average True Range (ATR)
- SCD 0.17
- ACIU 0.20
- MACD
- SCD 0.01
- ACIU -0.03
- Stochastic Oscillator
- SCD 68.64
- ACIU 20.00
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.